Los Angeles, California 90095

  • Vulvar Intraepithelial Neoplasia

Purpose:

This phase II trial studies the effect of pembrolizumab on high-grade vulvar, vaginal, and cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.


Study summary:

PRIMARY OBJECTIVE: I. Clinical response rate at 6 months - percent of patients with complete response at 6 months. SECONDARY OBJECTIVES: I. Histologic response rate at 6 months - percent of patients with regression from grade 2 or 3 intraepithelial neoplasia or carcinoma in situ to a lower grade. II. Clinical complete response rate at 9 months and 12 months. III. For vulvar intraepithelial neoplasia (VIN) only, clinical partial response rate at 6 months, 9 months, and 12 months. IV. Safety and tolerability of pembrolizumab in patients with VIN, vaginal intraepithelial neoplasia (VaIN), and cervical intraepithelial neoplasia (CIN). EXPLORATORY OBJECTIVES: I. Evaluation of PD-L1 expression in VIN, VaIN, and CIN lesions as a biomarker of response to therapy. II. Evaluation of HPV status as a biomarker of response to therapy. III. Evaluation of HPV clearance as a surrogate endpoint. OUTLINE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 6 weeks for a minimum of 24 weeks (4 cycles) and up to a maximum of 24 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 8 weeks for up to 1 year.


Criteria:

Inclusion Criteria: - Female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of VIN, vaginal intraepithelial neoplasia (VaIN), or cervical intraepithelial neoplasia (CIN) grade 2 or 3 or carcinoma in situ (without invasive component) will be enrolled in this study - A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies: - Not a woman of childbearing potential (WOCBP) OR - A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment - The participant (or legally acceptable representative if applicable) provides written informed consent for the trial - Have visible disease on physical exam and/or colposcopy - Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue - For subjects with VaIN or CIN only, participants must be willing to consent to end-of-study biopsy after cycle 4 of treatment if there is an accessible lesion and biopsy is not contraindicated - Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. Evaluation of ECOG is to be performed within 7 days prior to the date of allocation/randomization - Absolute neutrophil count (ANC) >= 1500/microliter (uL)(specimens must be collected within 10 days prior to the start of study treatment) - Platelets >= 100 000/uL (specimens must be collected within 10 days prior to the start of study treatment) - Hemoglobin >= 9.0 g/dL or >= 5.6 mmol/L (specimens must be collected within 10 days prior to the start of study treatment) - Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks - Creatinine =< 1.5 x upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 30 mL/min for participant with creatinine levels > 1.5 x institutional ULN (specimens must be collected within 10 days prior to the start of study treatment) - Creatinine clearance (CrCl) should be calculated per institutional standard - Total bilirubin =< 1.5 x ULN OR direct bilirubin =< ULN for participants with total bilirubin levels > 1.5 x ULN (specimens must be collected within 10 days prior to the start of study treatment) - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (specimens must be collected within 10 days prior to the start of study treatment) - International normalized ratio (INR) OR prothrombin time (PT) =< 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants (specimens must be collected within 10 days prior to the start of study treatment) - Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants (specimens must be collected within 10 days prior to the start of study treatment) - The participant is willing to consent to photographs of lesions Exclusion Criteria: - A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. - Note: in the event that 72 hours have elapsed between the screening pregnancy test and the first dose of study treatment, another pregnancy test (urine or serum) must be performed and must be negative in order for subject to start receiving study medication - Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137) - Has received prior systemic therapy for VIN, VaIN, or CIN including investigational agents within the prior 4 weeks (could consider shorter interval for short half-life drugs) prior to allocation. - Note: Participants must have recovered from all adverse events (AEs) due to previous therapies to =< grade 1 or baseline. Participants with =< grade 2 neuropathy may be eligible. - Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment - Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=< 2 weeks of radiotherapy) to non-central nervous system (CNS) disease - Has received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist) are live attenuated vaccines and are not allowed - Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention. - Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug - Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. - Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, in situ cervical cancer, or other in-situ cancers - Has severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients - Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed - Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis - Has an active infection requiring systemic therapy - Has a known history of human immunodeficiency virus (HIV) infection - Note: No HIV testing is required unless mandated by local health authority - Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection. Note: no testing for hepatitis B and hepatitis C is required unless mandated by local health authority - Has a known history of active TB (Bacillus tuberculosis) - Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator - Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial - Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment - Has had an allogenic tissue/solid organ transplant


NCT ID:

NCT04712851


Primary Contact:

Principal Investigator
John A Glaspy, MD
UCLA / Jonsson Comprehensive Cancer Center

Tiffany Lai
Phone: 310-794-7274
Email: tlai@mednet.ucla.edu


Backup Contact:

N/A


Location Contact:

Los Angeles, California 90095
United States

Tiffany Lai
Phone: 310-794-7274
Email: tlai@mednet.ucla.edu

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 22, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.